research AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort
This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.


